The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
Multiple myeloma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)
Herdman, M., Gudex, C., Lloyd, A., Janssen, M., Kind, P., Parkin, D., Bonsel, G., & Badia, X. (2011) · Quality of Life Research · doi:10.1007/s11136-011-9903-x · Cited by 9,795
Renehan, A. G., Tyson, M., Egger, M., Heller, R. F., & Zwahlen, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60269-x · Cited by 5,219
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationAlaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araujo, I. B. D. O., Berti, E., Bhagat, G., Borges, A. M., Boyer, D., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,004
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationInternational Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Review of 1027 Patients With Newly Diagnosed Multiple Myeloma
Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Rajkumar, S. V., Offord, J. R., Larson, D. R., et al. (2003) · Mayo Clinic Proceedings · doi:10.4065/78.1.21 · Cited by 2,447
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445
Self-citationInitial genome sequencing and analysis of multiple myeloma
Chapman, M. A., Lawrence, M. S., Keats, J. J., Cibulskis, K., Sougnez, C., Schinzel, A. C., Harview, C. L., Brunet, J.-P., Ahmann, G. J., Adli, M., et al. (2011) · Nature · doi:10.1038/nature09837 · Cited by 1,433
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300439 · Cited by 1,171
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, T., Kumar, S., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817249 · Cited by 1,045
Self-citationEuropean Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications
Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastritis, E., van de Donk, N. W. C. J., Bruno, B., Sezer, O., Broijl, A., et al. (2015) · Haematologica · doi:10.3324/haematol.2014.117176 · Cited by 988
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C., Chng, W.-J., Moreau, P., Attal, M., Kyle, R. A., et al. (2016) · Blood · doi:10.1182/blood-2016-01-631200 · Cited by 928
Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma
Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070389 · Cited by 921
Durie, B. G. M., Hoering, A., Abidi, M. H., Rajkumar, S. V., Epstein, J., Kahanic, S. P., Thakuri, M., Reu, F., Reynolds, C. M., Sexton, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31594-x · Cited by 908
Randomized trial of lenalidomide versus observation in smoldering multiple myeloma
Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01740 · Cited by 908
Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationA Cellular Taxonomy of the Bone Marrow Stroma in Homeostasis and Leukemia
Baryawno, N., Przybylski, D., Kowalczyk, M. S., Kfoury, Y., Severe, N., Gustafsson, K., Kokkaliaris, K. D., Mercier, F., Tabaka, M., Hofree, M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.04.040 · Cited by 884
Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00464-7 · Cited by 857
Self-citationCilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M.-V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303379 · Cited by 827
Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M. T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61424-9 · Cited by 819
Lonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Preston, D. L., Kusumi, S., Tomonaga, M., Izumi, S., Ron, E., Kuramoto, A., Kamada, N., Dohy, H., Matsui, T., Nonaka, H., et al. (1994) · Radiation Research · doi:10.2307/3578893 · Cited by 803
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Benboubker, L., Dimopoulos, M. A., Dispenzieri, A., Catalano, J., Belch, A. R., Cavo, M., Pinto, A., Weisel, K., Ludwig, H., Bahlis, N., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402551 · Cited by 793
Self-citationIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
Self-citationPalumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis
Kastritis, E., Palladini, G., Minnema, M. C., Wechalekar, A. D., Jaccard, A., Lee, H. C., Sanchorawala, V., Gibbs, S., Mollee, P., Venner, C. P., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028631 · Cited by 702
Self-citationMcCarthy, P. L., Holstein, S. A., Petrucci, M. T., Richardson, P. G., Hulin, C., Tosi, P., Bringhen, S., Musto, P., Anderson, K. C., Caillot, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.6679 · Cited by 698
Voorhees, P. M., Kaufman, J. L., Laubach, J., Sborov, D. W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L. J., Anderson, L. D., et al. (2020) · Blood · doi:10.1182/blood.2020005288 · Cited by 693
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma.
Chari, A., Vogl, D. T., Gavriatopoulou, M., Nooka, A. K., Yee, A. J., Huff, C. A., Moreau, P., Dingli, D., Cole, C., Lonial, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903455 · Cited by 666
Self-citationAttal, M., Richardson, P. G., Rajkumar, S. V., San-Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32556-5 · Cited by 645
Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2312054 · Cited by 599
Walker, B. A., Boyle, E. M., Wardell, C. P., Murison, A., Begum, D. B., Dahir, N. M., Proszek, P. Z., Johnson, D. C., Kaiser, M. F., Melchor, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1503 · Cited by 567
Genomic complexity of multiple myeloma and its clinical implications
Manier, S., Salem, K. Z., Park, J., Landau, D. A., Getz, G., & Ghobrial, I. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.122 · Cited by 560
Self-citationMolecular Pathogenesis and a Consequent Classification of Multiple Myeloma
Bergsagel, P. L., & Kuehl, W. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.021 · Cited by 556
Cavo, M., Terpos, E., Nanni, C., Moreau, P., Lentzsch, S., Zweegman, S., Hillengass, J., Engelhardt, M., Usmani, S. Z., Vesole, D. H., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30189-4 · Cited by 544
Self-citationKim, J. H., Kim, J. W., Kim, Y. N., Kim, H. I., Kim, J. Y., Kwon, G. Y., Kim, K., & Jang, H. R. (2015) · Case Reports in Nephrology and Dialysis · doi:10.1159/000439267 · Cited by 538
Munshi, N. C., Avet-Loiseau, H., Rawstron, A. C., Owen, R. G., Child, J. A., Thakurta, A., Sherrington, P., Samur, M. K., Georgieva, A., Anderson, K. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3160 · Cited by 532
Berenson, J., Pflugmacher, R., Jarzem, P., Zonder, J., Schechtman, K., Tillman, J. B., Bastian, L., Ashraf, T., & Vrionis, F. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70008-0 · Cited by 524
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C., Holmberg, E., Mellqvist, U.-H., Landgren, O., Bjorkholm, M., Hultcrantz, M., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2015) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 524
Hillengass, J., Usmani, S., Rajkumar, S. V., Durie, B. G. M., Mateos, M.-V., Lonial, S., Joao, C., Anderson, K. C., García-Sanz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 516
Self-citationAugustson, B. M., Begum, G., Dunn, J. A., Barth, N. J., Davies, F., Morgan, G., Behrens, J., Smith, A., Child, J. A., & Drayson, M. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.2086 · Cited by 488
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
Richardson, P. G., Jacobus, S. J., Weller, E. A., Hassoun, H., Lonial, S., Raje, N. S., Medvedova, E., McCarthy, P. L., Libby, E. N., Voorhees, P. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204925 · Cited by 487
Chromosome translocations in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2001) · Oncogene · doi:10.1038/sj.onc.1204641 · Cited by 478
Dimopoulos, M., Kyle, R., Fermand, J.-P., Rajkumar, S. V., San Miguel, J., Chanan-Khan, A., Ludwig, H., Joshua, D., Mehta, J., Gertz, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299529 · Cited by 454
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
Walker, B. A., Mavrommatis, K., Wardell, C. P., Ashby, T. C., Bauer, M., Davies, F., Rosenthal, A., Wang, H., Qu, P., Hoering, A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0196-8 · Cited by 446
MYC Deregulation in Primary Human Cancers
Kalkat, M., De Melo, J., Hickman, K., Lourenco, C., Redel, C., Resetca, D., Tamachi, A., Tu, W., & Penn, L. (2017) · Genes · doi:10.3390/genes8060151 · Cited by 443
Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6
Ratta, M., Fagnoni, F., Curti, A., Vescovini, R., Sansoni, P., Oliviero, B., Fogli, M., Ferri, E., Della Cuna, G. R., Tura, S., et al. (2002) · Blood · doi:10.1182/blood.v100.1.230 · Cited by 442
Argyriou, A. A., Iconomou, G., & Kalofonos, H. P. (2008) · Blood · doi:10.1182/blood-2008-04-149385 · Cited by 432
Dimopoulos, M., Quach, H., Mateos, M.-V., Landgren, O., Leleu, X., Siegel, D., Weisel, K., Yang, H., Klippel, Z., Zahlten-Kumeli, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30734-0 · Cited by 430
D'Agostino, M., Cairns, D. A., Lahuerta, J. J., Wester, R., Bertsch, U., Waage, A., Zamagni, E., Mateos, M.-V., Dall'Olio, D., van de Donk, N. W. C. J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02614 · Cited by 429
Perrot, A., Lauwers-Cances, V., Corre, J., Robillard, N., Hulin, C., Chretien, M.-L., Dejoie, T., Maheo, S., Stoppa, A.-M., Pegourie, B., et al. (2018) · Blood · doi:10.1182/blood-2018-06-858613 · Cited by 417
Self-citationRacial disparities in incidence and outcome in multiple myeloma: a population-based study
Waxman, A. J., Mink, P. J., Devesa, S. S., Anderson, W. F., Weiss, B. M., Kristinsson, S. Y., McGlynn, K. A., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-07-298760 · Cited by 411
Chesi, M., Robbiani, D. F., Sebag, M., Chng, W. J., Affer, M., Tiedemann, R., Valdez, R., Palmer, S. E., Haas, S. S., Stewart, A. K., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.01.007 · Cited by 393
Görgün, G. T., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., Raje, N., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2013) · Blood · doi:10.1182/blood-2012-08-448548 · Cited by 393
Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00592-4 · Cited by 392
Self-citationTargeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Self-citationRichardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., Lindsay, J., Weisel, K., White, D., Facon, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30152-4 · Cited by 386
Bladé, J., Fernández-Llama, P., Bosch, F., Montolíu, J., Lens, X. M., Montoto, S., Cases, A., Darnell, A., Rozman, C., & Montserrat, E. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.17.1889 · Cited by 383
Cavo, M., Gay, F., Beksac, M., Pantani, L., Petrucci, M. T., Dimopoulos, M. A., Dozza, L., van der Holt, B., Zweegman, S., Oliva, S., et al. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30099-5 · Cited by 381
Clues to cancer etiology from studies of farmers.
Blair, A., Zahm, S. H., Pearce, N. E., Heineman, E., & Fraumeni, J. F. J. (1992) · Scandinavian Journal of Work, Environment & Health · doi:10.5271/sjweh.1578 · Cited by 379
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0037-4 · Cited by 354
Self-citationPrabhala, R. H., Pelluru, D., Fulciniti, M., Prabhala, H. K., Nanjappa, P., Song, W., Pai, C., Amin, S., Tai, Y.-T., Richardson, P. G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-246660 · Cited by 351
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Delimpasi, S., Beksac, M., Katodritou, E., Moreau, P., Baldini, L., Symeonidis, A., Bila, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00128-5 · Cited by 344
Self-citationGrosicki, S., Simonova, M., Spicka, I., Pour, L., Kriachok, I., Gavriatopoulou, M., Pylypenko, H., Auner, H. W., Leleu, X., Doronin, V., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32292-3 · Cited by 335
Self-citationEpidemiology, Staging, and Management of Multiple Myeloma
Padala, S. A., Barsouk, A., Barsouk, A., Rawla, P., Vakiti, A., Kolhe, R., Kota, V., & Ajebo, G. H. (2021) · Medical Sciences · doi:10.3390/medsci9010003 · Cited by 332
Cordonnier, C., Einarsdottir, S., Cesaro, S., Di Blasi, R., Mikulska, M., Rieger, C., de Lavallade, H., Gallo, G., Lehrnbecher, T., Engelhard, D., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30600-5 · Cited by 331
Ebrahim, S. (1995) · Social Science & Medicine · doi:10.1016/0277-9536(95)00116-o · Cited by 321
Extramedullary disease in multiple myeloma: a systematic literature review
Bladé, J., Beksac, M., Caers, J., Jurczyszyn, A., von Lilienfeld-Toal, M., Moreau, P., Rasche, L., Rosiñol, L., Usmani, S. Z., Zamagni, E., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00643-3 · Cited by 319
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site
Zelle-Rieser, C., Thangavadivel, S., Biedermann, R., Brunner, A., Stoitzner, P., Willenbacher, E., Greil, R., & Jöhrer, K. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0345-3 · Cited by 319
Walker, B. A., Wardell, C. P., Murison, A., Boyle, E. M., Begum, D. B., Dahir, N. M., Proszek, P. Z., Melchor, L., Pawlyn, C., Kaiser, M. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms7997 · Cited by 313
Pathogenesis and treatment of renal failure in multiple myeloma
Dimopoulos, M. A., Kastritis, E., Rosinol, L., Bladé, J., & Ludwig, H. (2008) · Leukemia · doi:10.1038/leu.2008.131 · Cited by 305
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
Lakshman, A., Rajkumar, S. V., Buadi, F. K., Binder, M., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Dingli, D., Fonder, A. L., Hayman, S. R., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0077-4 · Cited by 303
Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M. R., Knolle, P. A., Classen, S., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2005-09-3671 · Cited by 301
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Fermand, J.-P., Bridoux, F., Dispenzieri, A., Jaccard, A., Kyle, R. A., Leung, N., & Merlini, G. (2018) · Blood · doi:10.1182/blood-2018-04-839480 · Cited by 299
Dal Maso, L., & Franceschi, S. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0308 · Cited by 297
Costa, L. J., Brill, I. K., Omel, J., Godby, K., Kumar, S. K., & Brown, E. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2016002493 · Cited by 293
Sant, M., Minicozzi, P., Mounier, M., Anderson, L. A., Brenner, H., Holleczek, B., Marcos-Gragera, R., Maynadié, M., Monnereau, A., Osca-Gelis, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70282-7 · Cited by 291
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Mateos, M.-V., Kumar, S., Dimopoulos, M. A., González-Calle, V., Kastritis, E., Hajek, R., De Larrea, C. F., Morgan, G. J., Merlini, G., Goldschmidt, H., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00366-3 · Cited by 291
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors
Avet-Loiseau, H., Gerson, F., Magrangeas, F., Minvielle, S., Harousseau, J.-L., & Bataille, R. (2001) · Blood · doi:10.1182/blood.v98.10.3082 · Cited by 289
Chauhan, D., Singh, A. V., Brahmandam, M., Carrasco, R., Bandi, M., Hideshima, T., Bianchi, G., Podar, K., Tai, Y.-T., Mitsiades, C., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.08.019 · Cited by 286
Friedrich, M. J., Neri, P., Kehl, N., Michel, J., Steiger, S., Kilian, M., Leblay, N., Maity, R., Sankowski, R., Lee, H., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.008 · Cited by 285
Self-citationMoreau, P., Hulin, C., Macro, M., Caillot, D., Chaleteix, C., Roussel, M., Garderet, L., Royer, B., Brechignac, S., Tiab, M., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693580 · Cited by 278
Zhang, X., Donnan, P. T., Bell, S., & Guthrie, B. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0673-8 · Cited by 278
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
Maura, F., Bolli, N., Angelopoulos, N., Dawson, K. J., Leongamornlert, D., Martincorena, I., Mitchell, T. J., Fullam, A., Gonzalez, S., Szalat, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11680-1 · Cited by 278
Smith, G. (1998) · The Lancet · doi:10.1016/s0140-6736(00)80010-0 · Cited by 259
Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01531-2 · Cited by 252
Self-citationThe multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape
de Jong, M. M. E., Kellermayer, Z., Papazian, N., Tahri, S., Hofste op Bruinink, D., Hoogenboezem, R., Sanders, M. A., van de Woestijne, P. C., Bos, P. K., Khandanpour, C., et al. (2021) · Nature Immunology · doi:10.1038/s41590-021-00931-3 · Cited by 250
Cocks, K., Cohen, D., Wisløff, F., Sezer, O., Lee, S., Hippe, E., Gimsing, P., Turesson, I., Hajek, R., Smith, A., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.04.022 · Cited by 247
Cella, D., Kallich, J., McDermott, A., & Xu, X. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh235 · Cited by 246
Facon, T., Dimopoulos, M. A., Meuleman, N., Belch, A., Mohty, M., Chen, W.-M., Kim, K., Zamagni, E., Rodriguez-Otero, P., Renwick, W., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0539-0 · Cited by 238
Self-citationHealth related quality of life in a nationally representative sample of haematological patients
Johnsen, A. T., Tholstrup, D., Petersen, M. A., Pedersen, L., & Groenvold, M. (2009) · European Journal of Haematology · doi:10.1111/j.1600-0609.2009.01250.x · Cited by 237
Huang, J., Chan, S. C., Lok, V., Zhang, L., Lucero-Prisno, D. E., Xu, W., Zheng, Z.-J., Elcarte, E., Withers, M., & Wong, M. C. S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00165-x · Cited by 229
Extramedullary multiple myeloma
Bhutani, M., Foureau, D. M., Atrash, S., Voorhees, P. M., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-019-0660-0 · Cited by 228
Genomic patterns of progression in smoldering multiple myeloma
Bolli, N., Maura, F., Minvielle, S., Gloznik, D., Szalat, R., Fullam, A., Martincorena, I., Dawson, K. J., Samur, M. K., Zamora, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05058-y · Cited by 222
Brown, L. M., Gridley, G., Check, D., & Landgren, O. (2008) · Blood · doi:10.1182/blood-2007-10-121285 · Cited by 220
Raje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212
Self-citationTerpos, E., Zamagni, E., Lentzsch, S., Drake, M. T., García-Sanz, R., Abildgaard, N., Ntanasis-Stathopoulos, I., Schjesvold, F., de la Rubia, J., Kyriakou, C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30559-3 · Cited by 212
Self-citationA novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma
Noonan, K., Marchionni, L., Anderson, J., Pardoll, D., Roodman, G. D., & Borrello, I. (2010) · Blood · doi:10.1182/blood-2010-05-283895 · Cited by 210
Risk of cancer in people with AIDS
Grulich, A. E., Wan, X., Law, M. G., Coates, M., & Kaldor, J. M. (1999) · AIDS · doi:10.1097/00002030-199905070-00014 · Cited by 210
Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma
González, D., van der Burg, M., García-Sanz, R., Fenton, J. A., Langerak, A. W., González, M., van Dongen, J. J. M., San Miguel, J. F., & Morgan, G. J. (2007) · Blood · doi:10.1182/blood-2007-02-069625 · Cited by 208
Dimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J. R., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00223-1 · Cited by 195
Self-citationMateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30124-3 · Cited by 193
Ludwig, H., Novis Durie, S., Meckl, A., Hinke, A., & Durie, B. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0141 · Cited by 188
Bustoros, M., Sklavenitis-Pistofidis, R., Park, J., Redd, R., Zhitomirsky, B., Dunford, A. J., Salem, K., Tai, Y.-T., Anand, S., Mouhieddine, T. H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00437 · Cited by 187
Self-citationMerhi, M., Raynal, H., Cahuzac, E., Vinson, F., Cravedi, J. P., & Gamet-Payrastre, L. (2007) · Cancer Causes & Control · doi:10.1007/s10552-007-9061-1 · Cited by 187
Fernández de Larrea, C., Kyle, R., Rosiñol, L., Paiva, B., Engelhardt, M., Usmani, S., Caers, J., Gonsalves, W., Schjesvold, F., Merlini, G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00587-0 · Cited by 186
Walker, B. A., Wardell, C. P., Brioli, A., Boyle, E., Kaiser, M. F., Begum, D. B., Dahir, N. B., Johnson, D. C., Ross, F. M., Davies, F. E., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.13 · Cited by 181
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
Mitchell, J. S., Li, N., Weinhold, N., Försti, A., Ali, M., van Duin, M., Thorleifsson, G., Johnson, D. C., Chen, B., Halvarsson, B.-M., et al. (2016) · Nature Communications · doi:10.1038/ncomms12050 · Cited by 180
Genetics of multiple myeloma: another heterogeneity level?
Corre, J., Munshi, N. C., & Avet‐Loiseau, H. (2015) · Blood · doi:10.1182/blood-2014-10-567370 · Cited by 176
Turesson, I., Bjorkholm, M., Blimark, C. H., Kristinsson, S., Velez, R., & Landgren, O. (2018) · European Journal of Haematology · doi:10.1111/ejh.13083 · Cited by 174
Prevalence of Monoclonal Gammopathy of Undetermined Significance: A Systematic Review
Wadhera, R. K., & Rajkumar, S. V. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0337 · Cited by 171
Beider, K., Bitner, H., Leiba, M., Gutwein, O., Koren-Michowitz, M., Ostrovsky, O., Abraham, M., Wald, H., Galun, E., Peled, A., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2207 · Cited by 171
Bailur, J. K., McCachren, S. S., Doxie, D. B., Shrestha, M., Pendleton, K., Nooka, A. K., Neparidze, N., Parker, T. L., Bar, N., Kaufman, J. L., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.127807 · Cited by 171
Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
Zhou, L., Yu, Q., Wei, G., Wang, L., Huang, Y., Hu, K., Hu, Y., & Huang, H. (2021) · BMC Cancer · doi:10.1186/s12885-021-08280-y · Cited by 170
Racial and ethnic disparities in hematologic malignancies
Kirtane, K., & Lee, S. J. (2017) · Blood · doi:10.1182/blood-2017-04-778225 · Cited by 168
Qiang, Y.-W., Barlogie, B., Rudikoff, S., & Shaughnessy, J. D. (2008) · Bone · doi:10.1016/j.bone.2007.12.006 · Cited by 167
Rejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J. M., Bräunlein, E., dos Santos, D. M. C., Freeman, C. L. L., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 165
Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk
Chubb, D., Weinhold, N., Broderick, P., Chen, B., Johnson, D. C., Försti, A., Vijayakrishnan, J., Migliorini, G., Dobbins, S. E., Holroyd, A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2733 · Cited by 164
Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk
Broderick, P., Chubb, D., Johnson, D. C., Weinhold, N., Försti, A., Lloyd, A., Olver, B., Ma, Y. P., Dobbins, S. E., Walker, B. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.993 · Cited by 163
Pathogenesis of myeloma bone disease
Roodman, G. (2004) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2004.01.001 · Cited by 163
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 163
Landgren, O., Rajkumar, S. V., Pfeiffer, R. M., Kyle, R. A., Katzmann, J. A., Dispenzieri, A., Cai, Q., Goldin, L. R., Caporaso, N. E., Fraumeni, J. F., et al. (2010) · Blood · doi:10.1182/blood-2010-01-262394 · Cited by 162
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis
Barwick, B. G., Neri, P. E., Bahlis, N. J., Nooka, A. K., Dhodapkar, M. V., Jaye, D. L., Hofmeister, C. C., Kaufman, J. L., Gupta, V. A., Auclair, D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09555-6 · Cited by 162
Self-citationMYC dysregulation in the progression of multiple myeloma
MMRF CoMMpass Network, Misund, K., Keane, N., Stein, C. K., Asmann, Y. W., Day, G., Welsh, S., Van Wier, S. A., Riggs, D. L., Ahmann, G., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0543-4 · Cited by 161
Dissecting racial disparities in multiple myeloma
Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. L., & Rebbeck, T. R. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0284-7 · Cited by 159
Myeloid-derived suppressor cells: The green light for myeloma immune escape
Malek, E., Lima, M. J. G. D., Letterio, J. J., Kim, B., Finke, J. H., Driscoll, J. J., & Giralt, S. (2016) · Blood Reviews · doi:10.1016/j.blre.2016.04.002 · Cited by 158
Sigurdardottir, E. E., Turesson, I., Lund, S. H., Lindqvist, E. K., Mailankody, S., Korde, N., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.23 · Cited by 153
Frequency of “Abnormal” Serum Globulins (M‐Components) in the Aged
Hällén, J. (1963) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1963.tb17460.x · Cited by 152
Myeloma bone disease: Pathophysiology and management
Silbermann, R. W., & Roodman, G. D. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.04.001 · Cited by 150
Haÿ, E., Laplantine, E., Geoffroy, V., Frain, M., Kohler, T., Müller, R., & Marie, P. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00349-08 · Cited by 150
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Boccadoro, M., Moreau, P., Miguel, J. F. S., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T. T. F., Driessen, C., Hájek, R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01016-0 · Cited by 150
Self-citationRögnvaldsson, S., Löve, Þ. J., Þorsteinsdóttir, S., Reed, E. R., Óskarsson, J. Þ., Pétursdóttir, Í., Sigurðardóttir, G. Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00480-w · Cited by 143
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Reynolds, G. K., Cliff, E. R. S., Mohyuddin, G. R., Popat, R., Midha, S., Ng, M., Harrison, S. J., Kesselheim, A. S., & Teh, B. W. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010539 · Cited by 143
Lin, Y., Raje, N. S., Berdeja, J. G., Siegel, D. S. D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J. M., Maus, M. V., Massaro, M., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02496-0 · Cited by 143
Went, M., Sud, A., Försti, A., Halvarsson, B.-M., Weinhold, N., Kimber, S. T., van Duin, M., Þorleifsson, G., Holroyd, A., Johnson, D. C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04989-w · Cited by 137
Terpos, E., Trougakos, I. P., Gavriatopoulou, M., Papassotiriou, I., Sklirou, A. D., Ntanasis‐Stathopoulos, I., Papanagnou, E., Fotiou, D., Kastritis, E., & Dimopoulos, M. A. (2021) · Blood · doi:10.1182/blood.2021011904 · Cited by 137
Self-citationKaiser, M., Hall, A., Walker, K., Sherborne, A. L., Tute, R. M. D., Newnham, N., Roberts, S., Ingleson, E., Bowles, K. M., Garg, M. K., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02567 · Cited by 137
Ailawadhi, S., Parikh, K., Abouzaid, S., Zhou, Z., Tang, W., Clancy, Z., Cheung, C., Zhou, Z., & Xie, J. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000308 · Cited by 134
Meta-analyses of multiple myeloma and farming
Khuder, S., & Mutgi, A. B. (1997) · American Journal of Industrial Medicine · Cited by 130
Revealing the Impact of Structural Variants in Multiple Myeloma
Rustad, E. H., Yellapantula, V. D., Głodzik, D., Maclachlan, K. H., Diamond, B. T., Boyle, E. M., Ashby, C., Blaney, P., Gundem, G., Hultcrantz, M. L., et al. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0132 · Cited by 130
Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129
Terpos, E., Berenson, J. R., Cook, R. J., Lipton, A., & Coleman, R. E. (2010) · Leukemia · doi:10.1038/leu.2010.62 · Cited by 124
Self-citationOutcome disparities in multiple myeloma: a SEER ‐based comparative analysis of ethnic subgroups
Ailawadhi, S., Aldoss, I. T., Yang, D., Razavi, P., Cozen, W., Sher, T., & Chanan-Khan, A. A. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09124.x · Cited by 124
Mechanisms of Light Chain Injury along the Tubular Nephron
Sanders, P. W. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012040388 · Cited by 124
Garcés, J., Cedena, M., Puig, N., Burgos, L., Pérez, J. J., Cordón, L., Flores-Montero, J. A., Sanoja-Flores, L., Calasanz, M. J., Oriol, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01365 · Cited by 123
Munshi, N. C., Anderson, L. D., Shah, N. D., Jagannath, S., Berdeja, J. G., Lonial, S., Raje, N. S., Siegel, D. S. D., Lin, Y., Oriol, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.8503 · Cited by 121
High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions
Hagen, P. A., Zhang, J., & Barton, K. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00679-5 · Cited by 120
Renal Improvement in Myeloma with Bortezomib plus Plasma Exchange
Burnette, B. L., Leung, N., & Rajkumar, S. V. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1101834 · Cited by 118
Leone, P., Berardi, S., Frassanito, M. A., Ria, R., Re, V. D., Cicco, S., Battaglia, S., Ditonno, P., Dammacco, F., Vacca, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-623975 · Cited by 117
Maura, F., Petljak, M., Lionetti, M., Cifola, I., Liang, W. S., Pinatel, E., Alexandrov, L. B., Fullam, A., Martin, S., Dawson, K. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.345 · Cited by 117
Risk Factors for Multiple Myeloma: A Systematic Review of Meta-Analyses
Sergentanis, T. Ν., Zagouri, F., Τσιλιμιδός, Γ., Tsagianni, A., Tseliou, M., Dimopoulos, M. A., & Ψαλτοπούλου, Θ. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.06.003 · Cited by 114
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
Eby, C. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07577.x · Cited by 114
Noll, J. E., Williams, S. A., Tong, C. M., Wang, H., Quach, J., Purton, L. E., Pilkington, K. R., To, L. B., Evdokiou, A., Gronthos, S., et al. (2013) · Haematologica · doi:10.3324/haematol.2013.090977 · Cited by 114
Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M., Leleu, X., LeBlanc, R., Suzuki, K., Raab, M. S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.21.02815 · Cited by 114
Osborne, T. R., Ramsenthaler, C., Siegert, R. J., Edmonds, P. M., Schey, S., & Higginson, I. J. (2012) · European Journal Of Haematology · doi:10.1111/ejh.12012 · Cited by 108
Madduri, D., Usmani, S. Z., Jagannath, S., Singh, I., Zudaire, E., Yeh, T., Allred, A. J., Banerjee, A., Goldberg, J. D., Schecter, J. M., et al. (2019) · Blood · doi:10.1182/blood-2019-121731 · Cited by 108
Complications of Multiple Myeloma
Bladé, J., & Rosiñol, L. (2007) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2007.08.006 · Cited by 107
Incidence trends for twelve cancers in younger adults—a rapid review
di Martino, E., Smith, L., Bradley, S. H., Hemphill, S., Wright, J. M., Renzi, C., Bergin, R. J., Emery, J. D., & Neal, R. D. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01704-x · Cited by 104
Avet‐Loiseau, H., Miguel, J. F. S., Casneuf, T., Iida, S., Lonial, S., Usmani, S. Z., Spencer, A. G., Moreau, P., Plesner, T., Weisel, K. C., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01814 · Cited by 103
Self-citationGiannakoulas, N. C., Ntanasis‐Stathopoulos, I., & Terpos, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094462 · Cited by 103
Self-citationLindqvist, E. K., Goldin, L. R., Landgren, O., Blimark, C. H., Mellqvist, U., Turesson, I., Wåhlin, A., Björkholm, M., & Kristinsson, S. Y. (2011) · Blood · doi:10.1182/blood-2011-04-347559 · Cited by 102
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma
Dahl, I. M. S., Rasmussen, T., Kaurić, G., & Husebekk, A. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03258.x · Cited by 102
Multiple myeloma and family history of cancer among blacks and whites in the U.S.
Brown, L. M., Linet, M. S., Greenberg, R. S., Silverman, D. T., Hayes, R. B., Swanson, G. M., Schwartz, A. G., Schoenberg, J. B., Pottern, L. M., & Fraumeni, J. F. (1999) · Cancer · Cited by 102
Larráyoz, M., Garcia-Barchino, M. J., Celay, J., Etxebeste, A., Jiménez, M., Pérez, C., Ordóñez, R., Cobaleda, C., Botta, C., Fresquet, V., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02178-3 · Cited by 101
Hari, P., Pasquini, M. C., Stadtmauer, E. A., Fraser, R. A., Fei, M., Devine, S. M., Efebera, Y. A., Geller, N. L., Horowitz, M. M., Koreth, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.8506 · Cited by 99
Gay, F., Roeloffzen, W. W. H., Dimopoulos, M. A., Rosiñol, L., van der Klift, M., Mina, R., Oriol, A., Katodritou, E., Wu, K. L., Rodríguez‐Otero, P., et al. (2023) · Blood · doi:10.1182/blood-2023-177546 · Cited by 99
Winston, D. J., Mullane, K. M., Cornely, O. A., Boeckh, M. J., Brown, J. W., Pergam, S. A., Trociukas, I., Žák, P., Craig, M., Papanicolaou, G. A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30631-7 · Cited by 97
Bone Disease in Multiple Myeloma: Biologic and Clinical Implications
Bernstein, Z. S., Kim, E. B., & Raje, N. S. (2022) · Cells · doi:10.3390/cells11152308 · Cited by 97
El-Khoury, H., Lee, D. J., Alberge, J.-B., Redd, R., Cea-Curry, C. J., Perry, J., Barr, H., Murphy, C., Sakrikar, D., Barnidge, D., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00069-2 · Cited by 94
Prevalence of smoldering multiple myeloma based on nationwide screening
Thorsteinsdóttir, S., Gíslason, G. K., Aspelund, T., Rögnvaldsson, S., Óskarsson, J. Þ., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Viðarsson, B., Önundarson, P. T., Agnarsson, B. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02183-6 · Cited by 93
Gay, F., Cerrato, C., Petrucci, M. T., Zambello, R., Gamberi, B., Ballanti, S., Omedè, P., Palmieri, S., Troia, R., Spada, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.8002 · Cited by 91
Ailawadhi, S., Jacobus, S. J., Sexton, R., Stewart, A. K., Dispenzieri, A. A., Hussein, M. A., Zonder, J. A., Crowley, J. J., Hoering, A., Barlogie, B., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0102-7 · Cited by 88
Notch-directed microenvironment reprogramming in myeloma: a single path to multiple outcomes
Colombo, M., Mirandola, L., Platonova, N., Apicella, L., Basile, A., Figueroa, A., Cobos, E., Chiriva‐Internati, M., & Chiaramonte, R. (2013) · Leukemia · doi:10.1038/leu.2013.6 · Cited by 87
Cowan, A., Ferrari, F., Freeman, S. S., Redd, R., El-Khoury, H., Perry, J., Patel, V., Kaur, P., Barr, H., Lee, D. J., et al. (2023) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00386-6 · Cited by 86
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
Rajkumar, S. V., & Harousseau, J. L. (2016) · Blood · doi:10.1182/blood-2016-09-692947 · Cited by 84
Bianchi, G., Kyle, R. A., Colby, C. L., Larson, D. R., Kumar, S. K., Katzmann, J. A., Dispenzieri, A. A., Therneau, T. M., Cerhan, J. R., Melton, L. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-277566 · Cited by 80
Favaloro, J., Brown, R. D., Aklilu, E., Yang, S., Suen, H., Hart, D. N. J., Fromm, P. D., Gibson, J., Khoo, L., Ho, P. J., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.825905 · Cited by 80
Mian, H. S., McCurdy, A. B. R., Giri, S., Grant, S. J., Rochwerg, B. N., Winks, E., Rosko, A. E., Engelhardt, M. M., Pawlyn, C., Cook, G., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-022-00779-2 · Cited by 80
How I treat multiple myeloma in geriatric patients
Facon, T. T. F., Leleu, X. P., & Manier, S. (2023) · Blood · doi:10.1182/blood.2022017635 · Cited by 79
Self-citationAlterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma
Pazina, T., Macfarlane, A. W., Bernabei, L. L., Dulaimi, E., Kotcher, R. E., Yam, C., Bezman, N., Robbins, M. D. H., Ross, E. A., Campbell, K. S., et al. (2021) · Cancers · doi:10.3390/cancers13020226 · Cited by 78
Marinac, C. R., Birmann, B. M., Lee, I.-M. M., ROSNER, B. A., Townsend, M. K., Giovannucci, E. L., Rebbeck, T. R., Buring, J. E., & Colditz, G. A. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0010-4 · Cited by 76
Dejoie, T., Corre, J., Caillon, H., Hulin, C., Perrot, A., Caillot, D., Boyle, E. M., Chrétien, M., Fontan, J., Belhadj, K., et al. (2016) · Blood · doi:10.1182/blood-2016-07-726778 · Cited by 74
Self-citationMcShane, C. M., Murray, L., Landgren, O., O’Rorke, M. A., Korde, N., Kunzmann, A. T., Ismail, M. R., & Anderson, L. A. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0695 · Cited by 71
Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury
Ying, W., Li, X., Rangarajan, S., Feng, W., Curtis, L. M., & Sanders, P. W. (2019) · Journal of Clinical Investigation · doi:10.1172/jci125517 · Cited by 71
Signaling Pathway Mediating Myeloma Cell Growth and Survival
Hideshima, T., & Anderson, K. C. (2021) · Cancers · doi:10.3390/cancers13020216 · Cited by 70
Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment
Berardi, S., Ria, R., Reale, A., Luisi, A. D., Catacchio, I., Moschetta, M., & Vacca, A. (2013) · Journal of Oncology · doi:10.1155/2013/183602 · Cited by 70
Delforge, M., Shah, N. D., Miguel, J. F. S., Braverman, J., Dhanda, D. S., Shi, L., Guo, S., Yu, P., Liao, W., Campbell, T., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021005913 · Cited by 70
Cited by
Structural basis for the midnolin-proteasome pathway and its role in suppressing myeloma
Nardone, C., Gao, J., Seo, H.-S., Mintseris, J., Ort, L., Yip, M. C. J., Negasi, M., Besschetnova, A. K., Kamitaki, N., Gygi, S. P., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.05.030 · Cited by 22
Metadata
- Authors
- Malard, F., Neri, P., Bahlis, N. J., Terpos, E., Moukalled, N., Hungria, V. T. M., Manier, S., & Mohty, M.
- Venue
- Nature Reviews Disease Primers
- Published
- 2024-06-27
- Volume
- 10
- Issue
- 1
- Pages
- 45-45
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4400094382
- Cited by
- 337
- References
- 268
- FWCI
- 43.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.